ProThera Biologics

Executive Summary

ProThera Biologics is a US-based biotechnology company pioneering Inter-alpha Inhibitor Proteins (IAIP), a novel class of naturally occurring human plasma proteins that modulate multiple inflammatory pathways. The company's therapeutic approach targets severe, life-threatening inflammatory diseases such as severe pneumonia, stroke, and neonatal conditions, where dysregulated inflammation leads to high mortality and disability. By restoring immune regulation rather than blocking single cytokines, IAIP offers a potentially broader and safer treatment option. The company has been operating since 2001 and is privately held, with its platform showing promise in preclinical and early clinical studies. ProThera's lead candidate is advancing toward key clinical milestones, with the potential to address significant unmet medical needs in acute inflammatory conditions. While the company remains in a relatively early stage, its unique mechanism of action and focus on indications with limited treatment options position it as a compelling player in the biologics space. The upcoming years are critical for demonstrating clinical proof-of-concept and securing partnerships or funding for late-stage development.

Upcoming Catalysts (preview)

• Q2 2026Phase 2a results for IAIP in severe pneumonia40% success
• Q4 2026FDA meeting to discuss Phase 3 design for neonatal inflammatory condition60% success
• Q3 2026Publication of preclinical data supporting IAIP in stroke70% success